Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis
Open Access
Abstract
Objective: To identify subsets of chronic obstructive pulmonary disease (COPD) patients who are more protected from exacerbations with the use of an inhaled corticosteroid/long-acting β 2 agonist (ICS/LABA) combination, compared with the use of LABA monotherapy. Design: Post hoc cluster analysis of patients from two randomised clinical trials of salmeterol/fluticasone propionate (SFC) and salmeterol (SAL) that had primary endpoints of moderate/severe exacerbation rates. Setting: Centres in North America. Participants: 1543 COPD patients were studied. Interventions: SFC 50/250 µg or SAL 50 µg, twice daily. Primary and secondary outcome measures: The analysis identified clusters of COPD patients more responsive to SFC versus SAL with respect to the annual rate of moderate/severe exacerbations and compared their baseline clinical characteristics. Results: Overall, SFC significantly reduced the annual rate of moderate/severe exacerbations as compared with SAL alone (rate ratio (RR)=0.701, p1 ) reversibility ≥12% (RR=0.67, p12% at baseline were significantly more likely to experience a reduction in COPD-associated exacerbations with SFC versus SAL alone. Trial registration: NCT00115492, NCT00144911Keywords
This publication has 48 references indexed in Scilit:
- Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional studyThe Lancet, 2012
- The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO studyEuropean Respiratory Journal, 2012
- COPD phenotype description using principal components analysisRespiratory Research, 2009
- Systemic manifestations and comorbidities of COPDEuropean Respiratory Journal, 2009
- Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary diseaseChronic Respiratory Disease, 2008
- Rationale for the Dutch HypothesisChest, 2004
- Impact of preventing exacerbations on deterioration of health status in COPDEuropean Respiratory Journal, 2004
- Furosemide: Progress in Understanding Its Diuretic, Anti-inflammatory, and Bronchodilating Mechanism of Action, and Use in the Treatment of Respiratory Tract DiseasesAmerican Journal of Therapeutics, 2002
- Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cellsAnnals of Allergy, Asthma & Immunology, 1999